Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals

Experimental and Therapeutic Medicine

Volumn 9, Issue 1, 2015, Pages 84-88

  Noguchi, Kaoru ^a   Hirota, Minoru ^a   Miyoshi, Toru ^b   Tani, Yoshinori ^a   Noda, Yoko ^b   Ito, Hiroshi ^b   Nanba, Seiji ^a  

^a OKAYAMA ROSAI HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Dipeptidyl peptidase 4; Endothelial function; Postprandial lipemia

Indexed keywords

APOLIPOPROTEIN B48; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VILDAGLIPTIN; VOGLIBOSE;

ADULT; ARTICLE; BRACHIAL ARTERY FLOW MEDIATED DILATION; BRONCHODILATATION; COOKIE LOADING TEST; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL TEST; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; MALE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VASODILATATION;

EID: 84919459448     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.2051     Document Type: Article

References (11)

1. Bansal S, Buring JE, Rifai N, et al: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298: 309-316, 2007.
2. Nordestgaard BG, Benn M, Schnohr P and Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298: 299-308, 2007.
3. Véniant MM, Pierotti V, Newland D, et al: Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J Clin Invest 100: 180-188, 1997.
4. Bae JH, Bassenge E, Kim KB, et al: Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis 155: 517-523, 2001.
5. van Oostrom AJ, Sijmonsma TP, Verseyden C, et al: Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res 44: 576-583, 2003.
6. DeFronzo RA, Fleck PR, Wilson CA and Mekki Q; Alogliptin Study 010 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: A randomized, double-blind, placebo-controlled study. Diabetes Care 31: 2315-2317, 2008.
7. Feng J, Zhang Z, Wallace MB, et al: Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 50: 2297-2300, 2007.
8. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O and Odaka H: Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 588: 325-332, 2008.
9. Matikainen N, Mänttäri S, Schweizer A, et al: Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49: 2049-2057, 2006.
10. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ and Couture P: Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 13: 366-373, 2011.
11. Noda Y, Miyoshi T, Oe H, et al: Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: A preliminary report. Cardiovasc Diabetol 12: 8, 2013.